Back to search
FDAFDA · Food and drugs·Recall number D-0093-2022

Cubicin (daptomycin for injection), 500 mg per vial, Single-dose vial, Rx only. Manuf. for: Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Whitehouse Station, NJ 08889, USA. Manuf. by: Baxter Pharmaceuticals LLC., Bloomington, IN 47403, USA, NDC: 67919-011-01

Published November 10, 2021 · Recall initiated: October 19, 2021

Summary

FDA records drug Class I recall D-0093-2022, published November 10, 2021 and initiated October 19, 2021. Recalling firm: MERCK SHARP & DOHME CORP; Status: Terminated; Reported quantity: 76,163 vials; Lot: Lot #: 934778, Exp. Date Jun 2022. Class I means a reasonable probability of serious adverse health consequences or death.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Presence of Particulate Matter: Identified as Glass Particles

What to do

Voluntary: Firm initiated · Press Release

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
MERCK SHARP & DOHME CORP
Distributor
Nationwide within the United States
Lot
Lot #: 934778, Exp. Date Jun 2022
Risk classification
Class I
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Cubicin (daptomycin for injection), 500 mg per vial, Single-dose vial, Rx only. Manuf. for: Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Whitehouse Station, NJ 08889, USA. Manuf. by: Baxter Pharmaceuticals LLC., Bloomington, IN 47403, USA, NDC: 67919-011-01 recalled?

Yes. FDA published recall D-0093-2022 on November 10, 2021. Reported hazard: Presence of Particulate Matter: Identified as Glass Particles

What should I do if I have this product?

Voluntary: Firm initiated · Press Release